课件：焦虑障碍的识别及治疗讲稿.pptVIP

* * 持续32周的临床试验，服用左洛复（n=83）的患者无一例出现激越、焦虑或失眠症状；而服用帕罗西汀（n=82）的患者7％出现激越、焦虑或失眠症状。两组之间具有显著的统计学差异（P0.01）。 * * 若干抗抑郁药各种断药症状发生情况比较-1 一项回顾性研究将服用氯咪帕明、帕罗西汀、氟伏沙明及舍曲林的171位患者出现的各种断药症状进行了比较，见图。 *与其他SSRIs相比，帕罗西汀组出现的眩晕、感觉异常及共济失调比例更高。 *舍曲林仅发现极少的眩晕现象。 *氯咪帕明组出现的感觉异常、多梦、恶心、失眠及易激惹症状最多。 * * * * * NICE——英国国家临床优选研究院 * J Clin Psychiatry. 2000 Aug;61(8):559-68.Related Articles, Links A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. There has been a paucity of well-designed studies comparing selective serotonin reuptake inhibitor (SSRI) medications in the treatment of depression in the elderly. This multicenter study was designed to examine the efficacy and safety of sertraline and fluoxetine in depressed elderly outpatients. A secondary objective was to examine the effects of SSRI treatment on quality of life and cognitive function. METHOD: Two hundred thirty-six outpatients 60 years of age and older who met DSM-III-R criteria for major depressive disorder received 1 week of single-blind placebo before being randomly assigned to 12 weeks of double-blind, parallel-group treatment with flexible daily doses of either sertraline (range, 50-100 mg) or fluoxetine (range, 20-40 mg). Primary efficacy measures consisted of the 24-item Hamilton Rating Scale for Depression and Clinical Global Impressions scale ratings. Secondary outcome assessments included clinician- and patient-rated measures of depression symptoms and factors, cognitive functioning, and quality of life, as well as plasma drug concentrations, which were correlated with clinical response. RESULTS: Both drugs produced a similarly positive response on the primary efficacy measures, with 12-week responder rates of 73% for sertraline and 71% for fluoxetine. Sertraline-treated patients showed statistically greater cognitive improvement on several measures. Both drugs were safe and well tolerated. CONCLUSION